These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28895848)

  • 1. Gene Editing: Regulatory and Translation to Clinic.
    Ando D; Meyer K
    Hematol Oncol Clin North Am; 2017 Oct; 31(5):797-808. PubMed ID: 28895848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates.
    Peterson CW; Wang J; Norman KK; Norgaard ZK; Humbert O; Tse CK; Yan JJ; Trimble RG; Shivak DA; Rebar EJ; Gregory PD; Holmes MC; Kiem HP
    Blood; 2016 May; 127(20):2416-26. PubMed ID: 26980728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases.
    Li L; Krymskaya L; Wang J; Henley J; Rao A; Cao LF; Tran CA; Torres-Coronado M; Gardner A; Gonzalez N; Kim K; Liu PQ; Hofer U; Lopez E; Gregory PD; Liu Q; Holmes MC; Cannon PM; Zaia JA; DiGiusto DL
    Mol Ther; 2013 Jun; 21(6):1259-69. PubMed ID: 23587921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding and overcoming adverse consequences of genome editing on hematopoietic stem and progenitor cells.
    Lee BC; Lozano RJ; Dunbar CE
    Mol Ther; 2021 Nov; 29(11):3205-3218. PubMed ID: 34509667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical applications of genome editing in HIV.
    Wang CX; Cannon PM
    Blood; 2016 May; 127(21):2546-52. PubMed ID: 27053530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I.
    Gomez-Ospina N; Scharenberg SG; Mostrel N; Bak RO; Mantri S; Quadros RM; Gurumurthy CB; Lee C; Bao G; Suarez CJ; Khan S; Sawamoto K; Tomatsu S; Raj N; Attardi LD; Aurelian L; Porteus MH
    Nat Commun; 2019 Sep; 10(1):4045. PubMed ID: 31492863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editing the Trypanosoma cruzi genome with zinc finger nucleases.
    Burle-Caldas GA; Grazielle-Silva V; Soares-Simões M; Schumann Burkard G; Roditi I; DaRocha WD; Teixeira SM
    Mol Biochem Parasitol; 2017 Mar; 212():28-32. PubMed ID: 28108186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Historical Perspective on the Current Renaissance for Hematopoietic Stem Cell Gene Therapy.
    Kohn DB
    Hematol Oncol Clin North Am; 2017 Oct; 31(5):721-735. PubMed ID: 28895843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclease-free Adeno-Associated Virus-Mediated Il2rg Gene Editing in X-SCID Mice.
    Hiramoto T; Li LB; Funk SE; Hirata RK; Russell DW
    Mol Ther; 2018 May; 26(5):1255-1265. PubMed ID: 29606506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.
    Holt N; Wang J; Kim K; Friedman G; Wang X; Taupin V; Crooks GM; Kohn DB; Gregory PD; Holmes MC; Cannon PM
    Nat Biotechnol; 2010 Aug; 28(8):839-47. PubMed ID: 20601939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-editing Technologies for Gene and Cell Therapy.
    Maeder ML; Gersbach CA
    Mol Ther; 2016 Mar; 24(3):430-46. PubMed ID: 26755333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ctrl-Alt-inDel: genome editing to reprogram a cell in the clinic.
    Urnov FD
    Curr Opin Genet Dev; 2018 Oct; 52():48-56. PubMed ID: 29879620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromatin structure of two genomic sites for targeted transgene integration in induced pluripotent stem cells and hematopoietic stem cells.
    van Rensburg R; Beyer I; Yao XY; Wang H; Denisenko O; Li ZY; Russell DW; Miller DG; Gregory P; Holmes M; Bomsztyk K; Lieber A
    Gene Ther; 2013 Feb; 20(2):201-14. PubMed ID: 22436965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockout of targeted gene in porcine somatic cells using zinc-finger nuclease.
    Hisamatsu S; Sakaue M; Takizawa A; Kato T; Kamoshita M; Ito J; Kashiwazaki N
    Anim Sci J; 2015 Feb; 86(2):132-7. PubMed ID: 25187232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refining strategies to translate genome editing to the clinic.
    Cornu TI; Mussolino C; Cathomen T
    Nat Med; 2017 Apr; 23(4):415-423. PubMed ID: 28388605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemistry, manufacturing and controls for gene modified hematopoietic stem cells.
    Soni S; Kohn DB
    Cytotherapy; 2019 Mar; 21(3):358-366. PubMed ID: 30745225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-clinical safety assessment of novel drug modalities: Genome safety perspectives on viral-, nuclease- and nucleotide-based gene therapies.
    Lemmens M; Dorsheimer L; Zeller A; Dietz-Baum Y
    Mutat Res Genet Toxicol Environ Mutagen; 2024; 896():503767. PubMed ID: 38821669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene editing and its application for hematological diseases.
    Osborn MJ; Belanto JJ; Tolar J; Voytas DF
    Int J Hematol; 2016 Jul; 104(1):18-28. PubMed ID: 27233509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery technologies for genome editing.
    Yin H; Kauffman KJ; Anderson DG
    Nat Rev Drug Discov; 2017 Jun; 16(6):387-399. PubMed ID: 28337020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome editing for human gene therapy.
    Meissner TB; Mandal PK; Ferreira LM; Rossi DJ; Cowan CA
    Methods Enzymol; 2014; 546():273-95. PubMed ID: 25398345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.